Form 4: Director Daphne Karydas Trades Mineralys Therapeutics Stock

Director Daphne Karydas executed a Rule 10b5-1 trading plan, acquiring 3,000 shares and selling 3,000 shares of Mineralys Therapeutics, Inc. (MLYS) on March 31, 2026.

Summary

• Daphne Karydas, a Director at Mineralys Therapeutics, Inc. (MLYS), engaged in stock transactions on March 31, 2026.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan, adopted on December 30, 2025.
• Karydas acquired 3,000 shares of common stock at a price of $12.02 per share.
• Concurrently, Karydas disposed of 3,000 shares of common stock at a price of $25.00 per share.
• Following these transactions, Karydas beneficially owns 6,200 shares of common stock directly.
• Additionally, Karydas holds a stock option for 41,000 shares, with a portion vesting monthly and an expiration date of September 13, 2033.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative. While the Rule 10b5-1 plan indicates compliance, the sale of shares by a director at a significant profit, even if pre-planned, can be perceived as a signal of reduced conviction by management.

Positives

• The acquisition of 3,000 shares at $12.02 per share indicates a belief in the company's value at that price point.
• The existence of a Rule 10b5-1 plan demonstrates proactive and compliant insider trading strategy, mitigating concerns about opportunistic trading.
• The stock option holding of 41,000 shares suggests continued long-term alignment with the company's performance.

Negatives

• The sale of 3,000 shares at $25.00 per share, a higher price than the acquisition, represents a profit-taking action by a key insider.
• The net effect of the day's trading under the plan was a reduction in directly held common stock by 3,000 shares.

Risks

• The sale of shares by a director, even under a 10b5-1 plan, could be interpreted negatively by the market, potentially impacting share price.
• The significant difference between the acquisition price ($12.02) and the sale price ($25.00) for the same number of shares might raise questions about the timing and execution of the plan.

Future Outlook

The filing does not contain explicit forward-looking statements or guidance regarding future financial performance. However, the continued vesting of stock options suggests ongoing incentive for future performance.

Management Comments

• Transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on December 30, 2025.
• The stock option vests in 36 monthly installments beginning on October 13, 2023.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by a director is a common practice to diversify holdings or manage personal finances while adhering to insider trading regulations. The specific details of the acquisition and sale prices, however, warrant attention in the context of the company's current trading range.

Stakeholder Impact

• Shareholders may view the director's sale of stock, even under a plan, with some concern, potentially leading to short-term price pressure.
• Employees with stock options may be encouraged by the continued vesting schedule, aligning their interests with long-term company performance.

Next Steps

• Continued monthly vesting of stock options.
• Potential future transactions under the Rule 10b5-1 plan, if applicable.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions executed under a Rule 10b5-1 plan. While the sale of shares by a director at a profit could be a minor concern, the plan's existence mitigates against opportunistic trading. The acquisition at a lower price and the substantial stock option holdings suggest continued engagement. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis of the company's performance.

Keywords

SEC Form 4, Insider Trading, Mineralys Therapeutics, MLYS, Daphne Karydas, Rule 10b5-1, Stock Option, Beneficial Ownership, Director Transactions